Prescrire Int. 2016 Oct;25(175):232.
The only available trial, a non-comparative study with 63 patients, failed to determine the efficacy of ibrutinib. In contrast, adverse effects are numerous and sometimes severe, including haematological disorders. Further evaluation of ibrutinib in this setting is necessary.
唯一可用的试验是一项针对63名患者的非对照研究，未能确定伊布替尼的疗效。相比之下，不良反应众多，有时还很严重，包括血液系统疾病。因此有必要对伊布替尼在此种情况下进行进一步评估。
